Experimental Therapy Could Kill Cancer Cells by Disrupting Their Circadian Rhythms
Yummymoon / Pixabay

Experimental Therapy Could Kill Cancer Cells by Disrupting Their Circadian Rhythms

According to a story from Science Daily, an experimental therapy for cancer could shut down tumor cells using an innovative mechanism that disrupts their circadian rhythm functions. A concept study…

Continue Reading Experimental Therapy Could Kill Cancer Cells by Disrupting Their Circadian Rhythms
Company Plans Extension Study for Phase 3 Trial of Amyotrophic Lateral Sclerosis Drug
source: pixabay.com

Company Plans Extension Study for Phase 3 Trial of Amyotrophic Lateral Sclerosis Drug

According to a story from pm360online.com, the Orion Corporation, a pharmaceutical company based in Finland, has recently announced that it plans to continue its Phase 3 trial of levosimendan as…

Continue Reading Company Plans Extension Study for Phase 3 Trial of Amyotrophic Lateral Sclerosis Drug
Unusual Bardet-Biedl Syndrome Case Raises Questions About Cancer Risk
mohamed_hassan / Pixabay

Unusual Bardet-Biedl Syndrome Case Raises Questions About Cancer Risk

According to a story from Genetic Obesity News, the unusual case of a female Bardet-Biedl syndrome patient who also had endometrial cancer is causing researchers to wonder if the two…

Continue Reading Unusual Bardet-Biedl Syndrome Case Raises Questions About Cancer Risk
Company Earns Orphan Drug Designation for Autoimmune Hepatitis From the FDA
www_slon_pics / Pixabay

Company Earns Orphan Drug Designation for Autoimmune Hepatitis From the FDA

According to a story from finanznachrichten.de, the Swedish drug company Calliditas Therapeutics has recently announced that the US Food and Drug Administration (FDA) has given one of the company's experimental drugs…

Continue Reading Company Earns Orphan Drug Designation for Autoimmune Hepatitis From the FDA

New Combination Treatment Gains Approval for Chronic Lymphocytic Leukemia

According to a story from Rare Disease Report, the US Food and Drug Administration (FDA) has announced its approval of a combination therapy from Janssen which consists of ibrutinib plus…

Continue Reading New Combination Treatment Gains Approval for Chronic Lymphocytic Leukemia

Rett Syndrome Trial for a Potential Apnea Treatment will Finish by the End of 2019

Rett Syndrome Rett syndrome is a rare neurodevelopmental disorder. It affects females disproportionately, at a far greater rate than males. It causes cognitive, autonomic, and neurological dysfunction as well as a loss of…

Continue Reading Rett Syndrome Trial for a Potential Apnea Treatment will Finish by the End of 2019
Close Menu